| Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. | |
| | |
MedLine Citation:
|
PMID: 20880826 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To examine the incidence of cardiometabolic conditions and change in care costs for patients with schizophrenia treated with antipsychotic medications, medical and pharmacy claims from the South Carolina Medicaid program were used to compare the incidence rates for five cardiometabolic conditions in 2,231 patients with schizophrenia who were newly prescribed one of seven antipsychotic medications, using a retrospective cohort design spanning three years. Incidence and cumulative prevalence (pre-existing + incident) rates for the five cardiometabolic conditions were: 10%/23.3% for Type II diabetes mellitus, 7%/13.3% for obesity/excessive weight gain, 17%/20.9% for dyslipidemia, 4.5%/7.3% for high blood pressure, and 15.6%/41.8% for hypertension. After being treated with the antipsychotic medications examined, the odds of developing obesity/excessive weight gain, Type II diabetes mellitus, or dyslipidemia were not significantly related to any specific atypical agent compared to haloperidol. Incidence rates for elevated blood pressure and clinically diagnosed hypertension were higher for patients prescribed ziprasidone (Odds Ratio [OR]=2.41, Confidence Intervals [CI]=1.20-4.85; OR=1.83, CI=1.16-2.90, respectively) relative to those prescribed haloperidol. Cost results indicate significant differences over time in medical service and pharmacy costs in the group which developed incident cardiometabolic conditions. Individuals diagnosed with schizophrenia with moderate prevalence and incidence rates for these cardiometabolic conditions demonstrated substantially decreasing medical care costs over the three years examined, perhaps indicating a widening gap in access to needed services for conditions that are known mortality risk factors. |
| | |
Authors:
|
Jeanette M Jerrell; Roger S McIntyre; Avnish Tripathi |
Related Documents
:
|
12084416 - Sexual side effects of novel antipsychotic medications. 16504026 - Time to discontinuation of atypical versus typical antipsychotics in the naturalistic t... 17211716 - The relationship of antipsychotic medication class and adherence with treatment outcome... 7906526 - Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual ... 19824066 - Electromagnetic interference of communication devices on ecg machines. 17912536 - Health economic evaluation of ferucarbotran-enhanced mri in the diagnosis of liver meta... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Clinical schizophrenia & related psychoses Volume: 4 ISSN: 1935-1232 ISO Abbreviation: Clin Schizophr Relat Psychoses Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-30 Completed Date: 2010-11-30 Revised Date: 2011-05-06 |
Medline Journal Info:
|
Nlm Unique ID: 101312513 Medline TA: Clin Schizophr Relat Psychoses Country: United States |
Other Details:
|
Languages: eng Pagination: 161-8 Citation Subset: IM |
Affiliation:
|
Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, SC 29203, USA. jeanette.jerrell@uscmed.sc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Antipsychotic Agents / adverse effects, economics, therapeutic use* Blood Pressure / drug effects Cardiovascular Diseases / economics*, epidemiology* Cohort Studies Comorbidity Diabetes Mellitus, Type 2 / economics, epidemiology Dyslipidemias / economics, epidemiology Female Health Care Costs / statistics & numerical data* Humans Hypertension / economics, epidemiology Incidence Male Metabolic Diseases / economics*, epidemiology* Middle Aged Obesity / economics, epidemiology Odds Ratio Prescription Fees / statistics & numerical data Retrospective Studies Risk Factors Schizophrenia / drug therapy*, epidemiology* South Carolina / epidemiology Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents |
| Comments/Corrections | |
Comment In:
|
Clin Schizophr Relat Psychoses. 2011 Apr;5(1):54; author reply 54
[PMID:
21459740
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Multiple endocrine neoplasia 1: providing care for the family.
Next Document: Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoa...